COMMUNIQUÉS West-GlobeNewswire

BrightSpring Health Services, Inc. Reports Third Quarter 2024 Financial Results and Increases Full Year 2024 Guidance

01/11/2024 - 11:00

LOUISVILLE, Ky., Nov. 01, 2024 (GLOBE NEWSWIRE) -- BrightSpring Health Services, Inc. (“BrightSpring” or the “Company”) (NASDAQ: BTSG), a leading provider of home and community-based health services for complex [...]

Orion Corporation: Managers’ transactions – Henrik Stenqvist

01/11/2024 - 08:45

ORION CORPORATION MANAGERS’ TRANSACTIONS 1 NOVEMBER 2024 at 9.45 EET Orion Corporation: Managers’ transactions – Henrik Stenqvist Orion Corporation has received the following disclosure under Market Abuse Regulation (EU [...]

Nxera Pharma Operational Highlights and Consolidated Results for the Third Quarter and First Nine Months of 2024

01/11/2024 - 07:30

Tokyo, Japan and Cambridge, UK, 1 November 2024 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) – formerly known as Sosei Group or Sosei Heptares – provides an update on operational activities and reports [...]

Lexicon Announces Outcome of FDA Advisory Committee for Zynquista™ (sotagliflozin) as an Adjunct to Insulin Therapy for Glycemic Control in Adults with Type 1 Diabetes and Chronic Kidney Disease

31/10/2024 - 23:54

PDUFA target action date set for December 20, 2024 THE WOODLANDS, Texas, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the outcome of the U.S. Food and Drug [...]

Bionano Announces Closing of $3 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules

31/10/2024 - 21:30

SAN DIEGO, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the closing of its previously announced registered direct offering priced at-the-marker under Nasdaq rules for the [...]

Cognition Therapeutics Presents Poster of Participant Demographics from Phase 2 Dementia with Lewy Bodies Study at CTAD

31/10/2024 - 21:15

- Patient characteristics are consistent with other DLB studies - PURCHASE, N.Y., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. , (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company [...]

Supernus Presents Promising Data from Open-Label Phase 2a Study of SPN-820 Data in Major Depressive Disorder at Psych Congress 2024

31/10/2024 - 21:10

Participants in the Phase 2a study experienced rapid and meaningful decreases in depressive symptoms Suicidal ideation decreased by 80% SPN-820 was well-tolerated with few adverse events SPN-820 is a novel, first-in- [...]

INmune Bio Inc. Announces Third Quarter 2024 Results and Provides Business Update

31/10/2024 - 21:05

Company to Host Conference Call Today, October 31, at 4:30pm ET BOCA RATON, Fla., Oct. 31, 2024 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company [...]

LeMaitre Q3 2024 Financial Results

31/10/2024 - 21:05

BURLINGTON, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) -- LeMaitre (Nasdaq:LMAT), a provider of vascular devices, implants, and services, reported Q3 2024 results, announced a $0.16/share quarterly dividend, and provided [...]

MannKind Corporation to Hold 2024 Third Quarter Financial Results Conference Call on November 7, 2024

31/10/2024 - 21:05

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Oct. 31, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , announced today that its third quarter 2024 financial results will be released after market close on [...]

Tenax Therapeutics to Present at the Guggenheim Healthcare Innovation Conference

31/10/2024 - 21:05

CHAPEL HILL, N.C., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX), a Phase 3, development-stage pharmaceutical company focused on identifying, developing and commercializing products that [...]

Quoin Pharmaceuticals to Announce Third Quarter 2024 Financial Results on Thursday, November 7, 2024

31/10/2024 - 21:05

ASHBURN, Va., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage specialty pharmaceutical company focused on rare and orphan diseases, announced [...]

Zymeworks Provides Corporate Update and Reports Third Quarter 2024 Financial Results

31/10/2024 - 21:05

First patient dosed in Phase 1 clinical trial evaluating ZW171 in advanced mesothelin (MSLN)-expressing cancers Preclinical data presented on ZW220 and ZW251 at EORTC-NCI-AACR conference Our partner Jazz Pharmaceuticals [...]

Codexis Reports Third Quarter 2024 Financial Results

31/10/2024 - 21:05

Quarter Highlights Include Key Additions to Management Team and Extension of Cash Runway into 2027 with $31M Raise via ATM Facility Company Reiterates Full-year Financial Guidance; On Track to Achieve Product Revenue [...]

Theriva Biologics Selected as Finalist in International Competition for Merck KGaA's EMEA Advance Biotech Grant

31/10/2024 - 21:05

Winner to be Presented at BIO-Europe 2024 in Stockholm, Sweden ROCKVILLE, Md., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics [...]

Ardelyx Reports Third Quarter 2024 Financial Results and Provides Business Update

31/10/2024 - 21:02

IBSRELA generates $40.6 million in net product sales revenue; Company expects full year 2024 IBSRELA net sales revenue to be between $145 and $150 million XPHOZAH generates $51.5 million in net product sales revenue [...]

NeuroOne® Announces Expansion of Existing Distribution Agreement with Zimmer Biomet for Commercialization of OneRF™ Ablation System

31/10/2024 - 21:01

License Provides Exclusive Commercialization Rights for US Distribution and Certain OUS Markets Agreement expected to boost NeuroOne sales revenue and profitability EDEN PRAIRIE, Minn., Oct. 31, 2024 (GLOBE NEWSWIRE [...]

Iovance Biotherapeutics to Host Third Quarter and Year-to-Date 2024 Financial Results Conference Call and Webcast on Thursday, November 7, 2024

31/10/2024 - 21:01

Iovance also to Participate in Upcoming November Conferences SAN CARLOS, Calif., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing [...]

Lyell Immunopharma Completes Acquisition of ImmPACT Bio

31/10/2024 - 21:00

Acquisition strengthens Lyell’s clinical pipeline with the addition of IMPT-314, a dual-targeting CD19/CD20 CAR T-cell product candidate expected to initiate pivotal development in 2025 in patients in the 3 rd line [...]